Clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015

Based on clinical data and the opinions of interviewed thought leaders, Roche/Genentech/Chugai’s pertuzumab plus trastuzumab (Roche/Genentech/Chugai’s Herceptin) and docetaxel (Sanofi’s Taxotere, generics) will become health care advisory firm Decision Resources’ proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015, following its launch for the indication in 2012 in the USA and Europe and in 2013 in Japan.

“Pertuzumab plus trastuzumab and docetaxel has competitive advantages in efficacy over our current proprietary clinical gold-standard treatment, trastuzumab plus docetaxel,” said Decision Resources analyst Amy Duval.

Decision Resources’ analysis of the breast cancer drug market also finds that Roche/Genentech/Chugai’s trastuzumab-DM1 (T-DM1) is likely to initially enter later-lines of treatment before receiving approval for the first-line setting, which means it will gain use across all lines of therapy, fragmenting its patient share across lines of treatment and restricting its uptake in the first-line setting.